Grant of Warrants to Board Members, Management and Employees in Genmab A/S


Summary: Genmab A/S' board of directors grants 505,250 warrants to members of   
the board of directors, managers and employees of the company as well as the    
company's subsidiaries.                                                         

Copenhagen, Denmark; October 8, 2008 - Genmab A/S (OMX: GEN) announced today    
that on a board meeting the board decided to issue 505,250 warrants to members  
of the board of directors, managers and employees of the company as well as the 
company's subsidiaries                                                          
                                                                                
The exercise price for each warrant is DKK 272.00. Each warrant entitles the    
owner to subscribe one share of nominally DKK 1. On the basis of an exercise    
price of DKK 272.00 and by application of the Black-Scholes formula, the average
value of each warrant can be calculated as DKK 109.81 based on an interest rate 
of 4.21% and the historical volatility of Genmab A/S shares calculated at       
36.84%.                                                                         
                                                                                
The warrants vest in blocks of 25% one, two, three and four years after the     
grant date, and all warrants expire at the tenth anniversary of the grant date. 
The new warrants were granted pursuant to the warrant plan adopted by the board 
on August 3, 2004. Information concerning Genmab's warrant schemes can be found 
on www.genmab.com under the heading ‘warrant scheme'.                           

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using cutting-edge  
antibody technology, Genmab's world class discovery, development and            
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders.  As Genmab advances towards a commercial future, we remain committed 
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options.  For more information on Genmab's products and           
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. For a     
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com.  Genmab does   
not undertake any obligation to update or revise forward looking statements in  
this press release nor to confirm such statements in relation to actual results,
unless required by law.                                                         

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 47/2008                                              

###

Attachments

47_warrant_grant_081008_uk.pdf